Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Kuehrer

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Acta Chirurgica Iugoslavica|December 5, 2006
Multimodal treatment of metastatic colorectal cancerIrene Kuehrer
World Journal of Surgery|April 28, 2011
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancerKlaus Sahora, Irene Kuehrer, Martin Schindl, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
Acta Chirurgica Iugoslavica|December 5, 2006
Straight and colonic J-pouch reconstruction after low anterior resectionB Teleky, Barbara Jech, Judith Karner-Hanusch, et al.
Disease Markers|September 8, 2011
Platelet-stored angiogenesis factors: clinical monitoring is prone to artifactsPatrick Starlinger, Lejla Alidzanovic, Dominic Schauer, et al.
Neoplasia (New York, N.Y.)|May 3, 2011
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatmentPatrick Starlinger, Philipp Brugger, Dominic Schauer, et al.
Neoplasia (New York, N.Y.)|October 27, 2011
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapyPatrick Starlinger, Philipp Brugger, Christian Reiter, et al.
Anticancer Research|April 30, 2014
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancerKlaus Sahora, Martin Schindl, Irene Kuehrer, et al.
Surgery|September 7, 2010
NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancerKlaus Sahora, Irene Kuehrer, Axel Eisenhut, et al.
Medcomm|July 8, 2025
Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC TrialRebecca Zirnbauer, Simon Hametner, Jutta Bergler-Klein, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Acta Chirurgica Iugoslavica|December 5, 2006
Multimodal treatment of metastatic colorectal cancerIrene Kuehrer
World Journal of Surgery|April 28, 2011
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancerKlaus Sahora, Irene Kuehrer, Martin Schindl, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
Acta Chirurgica Iugoslavica|December 5, 2006
Straight and colonic J-pouch reconstruction after low anterior resectionB Teleky, Barbara Jech, Judith Karner-Hanusch, et al.
Disease Markers|September 8, 2011
Platelet-stored angiogenesis factors: clinical monitoring is prone to artifactsPatrick Starlinger, Lejla Alidzanovic, Dominic Schauer, et al.
Neoplasia (New York, N.Y.)|May 3, 2011
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatmentPatrick Starlinger, Philipp Brugger, Dominic Schauer, et al.
Neoplasia (New York, N.Y.)|October 27, 2011
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapyPatrick Starlinger, Philipp Brugger, Christian Reiter, et al.
Anticancer Research|April 30, 2014
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancerKlaus Sahora, Martin Schindl, Irene Kuehrer, et al.
Surgery|September 7, 2010
NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancerKlaus Sahora, Irene Kuehrer, Axel Eisenhut, et al.
Medcomm|July 8, 2025
Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC TrialRebecca Zirnbauer, Simon Hametner, Jutta Bergler-Klein, et al.
Pageof 2